MPS Pharmaa Ltd
₹ 3.66
0.00%
22 Jul
- close price
About
Established in 1997, Advik Laboratories is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The company deals in a wide range of pharmaceuticals formulations like Tablets, Capsules and Dry Syrups, etc.
Key Points
- Market Cap ₹ 6.99 Cr.
- Current Price ₹ 3.66
- High / Low ₹ 3.66 / 2.42
- Stock P/E
- Book Value ₹ 1.03
- Dividend Yield 0.00 %
- ROCE -9.15 %
- ROE -34.9 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.55 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 35.9%
- Company has a low return on equity of -21.1% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.86 | 30.27 | 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | |
| 31.14 | 27.43 | 11.43 | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.80 | |
| Operating Profit | 2.72 | 2.84 | 0.81 | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.80 |
| OPM % | 8.03% | 9.38% | 6.62% | -36.30% | -242.25% | -12.96% | -87.95% | -2,266.67% | ||||
| 0.27 | 0.01 | 0.00 | 0.00 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 | |
| Interest | 1.40 | 1.20 | 1.08 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.58 | 0.68 | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 |
| Profit before tax | 1.01 | 0.97 | -0.92 | -1.19 | -7.44 | -1.06 | -1.30 | -1.23 | -4.50 | -0.93 | -1.08 | -0.86 |
| Tax % | 50.50% | 50.52% | -26.09% | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% |
| 0.50 | 0.46 | -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | |
| EPS in Rs | 0.53 | 0.31 | -0.45 | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 22% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | 29% |
| 3 Years: | 49% |
| 1 Year: | 51% |
| Return on Equity | |
|---|---|
| 10 Years: | -20% |
| 5 Years: | -32% |
| 3 Years: | -21% |
| Last Year: | -35% |
Balance Sheet
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.35 | 15.03 | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 1.88 | 2.35 | 1.06 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 |
| 13.55 | 8.22 | 7.78 | 6.65 | 2.90 | 2.90 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | |
| 4.46 | 9.22 | 8.49 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.70 | |
| Total Liabilities | 29.24 | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 |
| 9.47 | 15.18 | 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | |
| CWIP | 0.00 | 0.00 | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 |
| 18.85 | 18.72 | 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | |
| Total Assets | 29.24 | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 |
Cash Flows
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 4.62 | 2.16 | 1.25 | 0.37 | -0.34 | 0.61 | -0.49 | -0.93 | -4.34 | -0.87 | -0.63 | |
| -0.29 | -6.39 | -0.44 | -0.05 | 0.63 | 0.30 | -0.22 | 0.46 | 1.54 | 0.46 | -0.10 | 0.12 | |
| 0.27 | 1.72 | -1.75 | -1.19 | -0.98 | 0.00 | -0.39 | 0.03 | -0.61 | 3.88 | 0.96 | 0.51 | |
| Net Cash Flow | 0.00 | -0.05 | -0.03 | 0.01 | 0.02 | -0.04 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
Ratios
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.43 | 104.30 | 229.02 | 1,154.48 | 532.08 | 344.47 | 1,147.77 | 365.00 | ||||
| Inventory Days | 115.62 | 94.81 | 274.40 | 6,543.93 | 50.05 | 58.94 | 253.72 | 4,015.00 | 4,562.50 | |||
| Days Payable | 34.54 | 62.46 | 123.03 | 556.19 | 15.95 | 14.48 | 71.22 | 876.00 | 1,825.00 | |||
| Cash Conversion Cycle | 146.52 | 136.65 | 380.39 | 7,142.22 | 566.19 | 388.94 | 1,330.27 | 3,504.00 | ||||
| Working Capital Days | 154.15 | 148.56 | 327.72 | 2,509.04 | 257.04 | 171.34 | 255.06 | 21,291.67 | ||||
| ROCE % | 10.26% | 8.61% | 0.65% | -4.48% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Jul - Submission of Certificate under Regulation 74(5) of SEBI(DP) Reg, 2018 for the quarter ended 30.06.2024
- Statement Of Investor Complaints For The Quarter Ended 30Th June, 2024 8 Jul
- Closure of Trading Window 29 Jun
- Certificate Of Non-Disqualification Of Directors Under Regulation 34(3) And Schedule V Para C Clause (10)(I) Of The SEBI (LODR) Regulations, 2015 For The Financial Year Ended 31St March, 2024 20 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Submission of newspaper publication w.r.t audited financial statements for the quarter and year ended 31.03.2024
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Portfolio:[1]
a) WHO - GMP Certified Generic Products:[2]
Antibacterial
Antiallergics
Antifungals
Analgesic
Antipyretic
Anti-inflammatory
Anthelminthic
Antihypertensive
Antimalarial
Antituberculotic
Corticosteroids
Erectile Dysfunction
Gastrointestinal agents
Sedatives
b) WHO - GMP Certified Ethical Products:[3]
Wibatol
Robial
Twosum
Majispa
Arfa Gel
Stibomin
Chewfe-C